Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 301–400 of 1,000
Mastrokolias, A., den Dunnen, J. T., van Ommen, G. B., Hoen, P. A. C. ’., & van Roon‐Mom, W. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-28 · Cited by 81
“Gene expression differences in peripheral whole blood have been used to determine signatures related to acute myeloid leukaemia [8], but also in neuropsychiatric disorders and Huntington’s disease where significant correlation was found between blood and brain gene expression [9,10].”
BackgroundGene Expression Profiling to Predict Outcome After Chemoradiation in Head and Neck Cancer
Pramana, J., van den Brekel, M. W. M., van Velthuysen, M. F., Wessels, L. F. A., Nuyten, D. S. A., Hofland, I., Atsma, D., Pimentel, N., Hoebers, F. J. P., Rasch, C. R. N., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.08.032 · Cited by 76
de Torrenté, L., Zimmerman, S. E., Suzuki, M., Christopeit, M., Greally, J. M., & Mar, J. C. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03892-w · Cited by 70
Zhou, J., Bi, C., Chng, W. J., Cheong, L. L., Liu, S. C., Mahara, S., Tay, K.-G., Zeng, Q., Li, J., Guo, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019798 · Cited by 69
“A search of the Oncomine database (December 09) revealed that PRL-3 was significantly overexpressed in FLT3-ITD positive AML as compared to FLT3-ITD negative AML (study name: Valk_leukemia, 78 vs 206 cases, p,0.001, Figure S3) [15], indicating a possible association between PRL-3 expression and FLT3-ITD mutation.”
BackgroundInfluentialCore-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Paschka, P., & Döhner, K. (2013) · Hematology · doi:10.1182/asheducation-2013.1.209 · Cited by 75
Monzó, M., Brunet, S., Urbano-Ispizúa, Á., Navarro, A., Perea, G., Esteve, J., Artells, R., Granell, M., Berlanga, J., Ribera, J., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3272 · Cited by 72
“8 M0 8 (7) 2 (3) M1 25 (23) 17 (23) M2 22 (20) 15 (21) M4 15 (13) 15 (21) M5 31 (28) 16 (22) M6 2 (2) 2 (3) AML and dysplasia 4 (4) 3 (4)”
Heterogeneity in refractory acute myeloid leukemia
Horibata, S., Gui, G., Lack, J., DeStefano, C. B., Gottesman, M. M., & Hourigan, C. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902375116 · Cited by 75
“Stem cell signatures previously identified as being predictive of outcomes and relapse in AML (16, 18) exhibit varying levels of activity across our refractory subgroups (Fig.”
BackgroundSaied, M. H., Marzec, J., Khalid, S., Smith, P., Down, T. A., Rakyan, V. K., Molloy, G., Raghavan, M., Debernardi, S., & Young, B. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033213 · Cited by 75
“Furthermore, we investigated the relationship between differential gene expression and DNA methylation by integrating our promoter MeDIP-seq data with published gene expression data [33,34,35].”
MethodMulloy, J. C., Jankovic, V. S., Wunderlich, M., Delwel, R., Cammenga, J., Krejci, O., Zhao, H., Valk, P. J. M., Löwenberg, B., & Nimer, S. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404701102 · Cited by 74
Self-citationAshton, J. M., Balys, M., Neering, S. J., Hassane, D. C., Cowley, G., Root, D. E., Miller, P. G., Ebert, B. L., McMurray, H. R., Land, H., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.024 · Cited by 68
Normal and leukaemic stem cells
Bonnet, D. A. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05596.x · Cited by 78
“Despite the clear benefit of using gene expression profiling to identify prognostic subclasses in adult AML, these results do not provide any information at the LSC level (Bullinger et al, 2004; Valk et al, 2004, 2005).”
BackgroundGuezguez, B., Almakadi, M., Benoit, Y. D., Shapovalova, Z., Rahmig, S., Fiebig‐Comyn, A., Casado, F. L., Tanasijevic, B., Bresolin, S., Masetti, R., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.11.012 · Cited by 68
Escudero, S., Zaganjor, E., Lee, S., Mill, C. P., Morgan, A. M., Crawford, E. B., Chen, J., Wales, T. E., Mourtada, R., Luccarelli, J., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.02.005 · Cited by 64
“Correlation Between MCL-1 Expression Level and Fatty Acid Metabolism in AML (A–”
BackgroundMethodInfluentialThe use of transcriptomic biomarkers for personalized medicine
Heidecker, B., & Hare, J. M. (2007) · Heart Failure Reviews · doi:10.1007/s10741-007-9004-7 · Cited by 67
“To date, most clinical demonstration of the utility of molecular signature analysis (MSA) are in oncology, where molecular signatures have been successfully identified that predict both clinical outcome and disease etiology [32–42].”
BackgroundHuang, T., Myklebust, L. M., Kjarland, E., Gjertsen, B. T., Pendino, F., Bruserud, Ø., Døskeland, S. O., & Lillehaug, J. R. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-31 · Cited by 67
“Also array-based AML gene expression profiling studies [9, 22- 24 ] underscore the heterogeneity of AML and the need for personalized therapy [25,26].”
BackgroundGenomics and proteomics: Emerging technologies in clinical cancer research
Chung, C. H., Levy, S., Chaurand, P., & Carbone, D. P. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.005 · Cited by 74
“has shown that there were 16 clusters expression-based subgroups) within 285 patients with ML and these clusters correlated with previously known, enetically defined subgroups by cytogenetics and FAB lassification as well as novel clusters [28].”
BackgroundResultMicroarrays and Clinical Investigations
Liu, E. T., & Karuturi, K. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048050 · Cited by 67
Handschuh, L. (2019) · Journal of Oncology · doi:10.1155/2019/7239206 · Cited by 73
Bonavida, B., & Kaufhold, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.011 · Cited by 69
Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients
Liersch, R., Gerß, J., Schliemann, C., Bayer, M. E., Schwöppe, C., Biermann, C., Appelmann, I., Keßler, T., Löwenberg, B., Büchner, T., et al. (2012) · Blood · doi:10.1182/blood-2011-11-389692 · Cited by 66
“Median follow-up, mo (range) 28 (1-103) 15 (1-70) 43 (1-213)”
Self-citationRubnitz, J. E., Gibson, B. E. S., & Smith, F. O. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.11.003 · Cited by 69
Neben, K., Schnittger, S., Brors, B., Tews, B., Kokocinski, F., Haferlach, T., Müller, J., Hahn, M., Hiddemann, W., Eils, R., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208344 · Cited by 73
“Although we cannot exclude that this problem in classification is related to the small sample size of this particular subgroup (n¼ 13), Valk et al. (2004) reported correspondingly that mutations in codon 12, 13, and 61 of the small RAS GTPases (NRAS and KRAS) resulted in no apparent gene expression…”
BackgroundResultINTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Tomlins, S. A., Rubin, M. A., & Chinnaiyan, A. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100047 · Cited by 66
Gadd45 in Modulation of Solid Tumors and Leukemia
Hoffman‐Liebermann, B., & Liebermann, D. A. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8289-5_2 · Cited by 68
Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients
Nicolas‐Virelizier, E., Ramus, C., Berthier, S., Arlotto, M., Bouamrani, A., Lefebvre, C., Morel, F., Garin, J., Ifrah, N., Berger, F. R., et al. (2010) · Leukemia · doi:10.1038/leu.2010.251 · Cited by 75
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia
Lim, Y., Gondek, L. P., Li, L., Wang, Q., Ma, H., Chang, E., Huso, D. L., Foerster, S., Marchionni, L., McGovern, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5731 · Cited by 68
A shared gene‐expression signature in innate‐like lymphocytes
Yamagata, T., Benoist, C., & Mathis, D. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00371.x · Cited by 65
Métais, J.-Y., & Dunbar, C. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300372 · Cited by 64
Kittleson, M. M., & Hare, J. M. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.05.007 · Cited by 64
Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Chalandon, Y., & Schwaller, J. (2005) · PubMed · Cited by 76
Crossman, L. C., Mori, M., Hsieh, Y. C., Lange, T., Paschka, P., Harrington, C. A., Krohn, K., Niederwieser, D. W., Hehlmann, R., Hochhaus, A., et al. (2005) · PubMed · Cited by 68
Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells
Shimabe, M., Goyama, S., Watanabe‐Okochi, N., Yoshimi, A., Ichikawa, M., Imai, Y., & Kurokawa, M. (2009) · Oncogene · doi:10.1038/onc.2009.288 · Cited by 69
“Analysis of gene expression data of 285 individuals with AML (Valk et al., 2004) showed the positive correlation between EVI-1 and PBX1 expression.”
BackgroundMethodInfluentialMYC oncogene in myeloid neoplasias
Delgado, M. D., Albajar, M., Gómez‐Casares, M. T., Batlle, A., & León, J. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0926-8 · Cited by 68
Hatzl, S., Geiger, O., Kuepper, M. K., Caraffini, V., Seime, T., Furlan, T., Nussbaumer, E., Wieser, R., Pichler, M., Scheideler, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3049 · Cited by 63
“For RKIP and miRNA array analysis in the Dutch-Belgian AML cohort II, a total of 214 AML patients were collected at the Erasmus University of Rotterdam, The Netherlands, as previously reported (11, 30-32).”
BackgroundMethodInfluentialMiari, K. E., Guzmán, M. L., Wheadon, H., & Williams, M. T. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.692800 · Cited by 64
“Importantly, through analysis of microarray datasets from three independent adult AML patient cohorts (Valk et al., 2004; Bullinger et al., 2008; Metzeler et al., 2008), Majeti et al.”
BackgroundTaskesen, E., Havermans, M., van Lom, K., Sanders, M. A., van Norden, Y., Bindels, E., Hoogenboezem, R., Reinders, M. J. T., Figueroa, M. E., Valk, P. J. M., et al. (2014) · Blood · doi:10.1182/blood-2013-07-512855 · Cited by 56
“0 (Santa Clara, CA).(13,14,25) Sample processing and quality control were carried out as described previously.”
BackgroundMethodInfluentialSelf-citationZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
Hartmann, L., Dutta, S., Opatz, S., Vosberg, S., Reiter, K., Leubolt, G., Metzeler, K. H., Herold, T., Bamopoulos, S. A., Bräundl, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11733 · Cited by 64
“Consistent with our findings, ZBTB7A mutations in 3 of 20 (15%) AML t(8;21) patients and 1 of 395 AML inv(16) patients were reported18 during the revision of the present manuscript.”
BackgroundResultInfluentialA pan-cancer analysis of prognostic genes
Anaya, J., Reon, B. J., Chen, W., Bekiranov, S., & Dutta, A. (2016) · PeerJ · doi:10.7717/peerj.1499 · Cited by 62
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia
Alberich-Jordà, M., Wouters, B., Balastik, M., Shapiro-Koss, C., Zhang, H., DiRuscio, A., Radomska, H. S., Ebralidze, A. K., Amabile, G., Ye, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65102 · Cited by 59
“We made use of the leukemic cell specimens of 2 independent and representative cohorts of AML patients (17, 32, 67).”
Self-citationBard-Chapeau, E. A., Gunaratne, J., Kumar, P., Chua, B. Q., Müller, J., Bard, F., Blackstock, W. P., Copeland, N. G., & Jenkins, N. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309310110 · Cited by 71
“Microarray data were ordered by mean of MECOM expression by using 277 patients with ovarian cancer (33) and 30 patients with AML (34), respectively.”
BackgroundInfluentialJinlong, S., Lin, F., Li, Y., Yu, L., & Weidong, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118099 · Cited by 61
“Mutations and gene expression signatures have been used to distinguish and identify different prognostic subgroups[2,3].”
BackgroundNakagawa, M. M., Shimabe, M., Watanabe‐Okochi, N., Arai, S., Yoshimi, A., Shinohara, A., Nishimoto, N., Kataoka, K., Sato, T., Kumano, K., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326710 · Cited by 69
Multiple myeloma cancer stem cells
Gao, M., Kong, Y., Yang, G., Gao, L., & Shi, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8154 · Cited by 59
Martínez, E., Yoshihara, K., Kim, H., Mills, G. M., Treviño, V., & Verhaak, R. G. W. (2014) · Oncogene · doi:10.1038/onc.2014.216 · Cited by 78
Self-citationSuh, H. C., Leeanansaksiri, W., Ji, M. H., Klarmann, K. D., Renn, K., Gooya, J. M., Smith, D., McNiece, I., Lugthart, S., Valk, P. J. M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.175 · Cited by 62
Self-citationYTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML
Chen, Z., Shao, Y.-L., Wang, L.-L., Lin, J., Zhang, J., Ding, Y., Gao, B.-B., Liu, D., & Gao, X. (2021) · Oncogene · doi:10.1038/s41388-021-01818-1 · Cited by 60
“To verify this result, the expression of YTHDF2 mRNA was measured in another microarray dataset [18] (Supplementary Table S2), which also showed its selective upregulation in t(8;21) AML (Fig.”
BackgroundChuang, M., Chiu, Y., Chou, W., Hou, H., Tseng, M., Kuo, Y.-Y., Chen, Y., Chuang, E. Y.-Y., & Tien, H. (2015) · Oncotarget · doi:10.18632/oncotarget.5390 · Cited by 66
The Molecular Pathology of Acute Myeloid Leukemia
Licht, J. D., & Sternberg, D. (2005) · Hematology · doi:10.1182/asheducation-2005.1.137 · Cited by 59
Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma
Hashizume, R. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2017-0018 · Cited by 63
Aubrey, B. J., Cutler, J. A., Bourgeois, W., Donovan, K. A., Gu, S. S., Hatton, C., Perlee, S. C., Perner, F., Rahnamoun, H., Theall, A. C. P., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00366-1 · Cited by 65
“Co-IP using antibodies specific to (1) MENIN or MLL1 and (2) IKAROS resulted in enrichment of IKAROS and MENIN, respectively (Fig.”
MethodInfluentialCahan, P., Ahmad, A. M., BURKE, H. B., Fu, S. W., Lai, Y., Florea, L., Dharker, N., Kobrinski, T., Kale, P., & McCaffrey, T. A. (2005) · Gene · doi:10.1016/j.gene.2005.07.008 · Cited by 61
Powell, J. A., Thomas, D., Barry, E. F., Kok, C. H., McClure, B. J., Tsykin, A., To, L. B., Brown, A. L., Lewis, I. D., Herbert, K. E., et al. (2009) · Blood · doi:10.1182/blood-2009-02-204818 · Cited by 58
“Median BM blasts, % (range) 67 (20-99) 55 (22-92) 70 (20-99) .”
Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias
Kvinlaug, B. T., Chan, W.-I., Bullinger, L., Ramaswami, M., Sears, C., Foster, D., Lazic, S. E., Okabe, R. O., Benner, A., Lee, B. H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0176 · Cited by 65
“In addition, gene expression studies have defined signatures downstream of many of these genetic lesions, allowing further molecular characterization (3,4).”
InfluentialSelf-citationGene selection via the BAHSIC family of algorithms
Song, L., Bedő, J., Borgwardt, K. M., Gretton, A., & Smola, A. J. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm216 · Cited by 62
“, 2001) (9, 10), and two with leukaemia (Bullinger et al., 2004; Valk et al., 2004) (16, 17).”
CD47: a new player in phagocytosis and xenograft rejection
Navarro–Álvarez, N., & Yang, Y. (2011) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.83 · Cited by 57
Preferential eradication of acute myelogenous leukemia stem cells by fenretinide
Zhang, H., Mi, J., Fang, H., Wang, Z., Wang, C., Wu, L., Zhang, B., Minden, M. D., Yang, W., Wang, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302352110 · Cited by 57
“AML outcome-related gene sets (39) and LSCspecific gene sets (4) (Dataset S2) were obtained from the indicated publications.”
BackgroundMethodRice, K. L., Hormaeche, I., Doulatov, S. R., Flatow, J. M., Grimwade, D. J., Mills, K., Leiva, M., Ablain, J., Ambardekar, C., McConnell, M. J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-206524 · Cited by 60
Cyproheptadine displays preclinical activity in myeloma and leukemia
Mao, X., Liang, S., Hurren, R., Gronda, M., Chow, S., Xu, G. W., Wang, X., Zavareh, R. B., Jamal, N., Messner, H. A., et al. (2008) · Blood · doi:10.1182/blood-2008-02-142687 · Cited by 56
DNA methylation as a pathogenic event and as a therapeutic target in AML
Schoofs, T., & Müller‐Tidow, C. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.013 · Cited by 60
Trisomy 8 in acute myeloid leukemia
Hemsing, A. L., Hovland, R., Tsykunova, G., & Reikvam, H. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1657400 · Cited by 64
Silva, F. P. G., Swagemakers, S. M. A., Erpelinck-Verschueren, C. A. J., Wouters, B. J., Delwel, R., Vrieling, H., van der Spek, P. J., Valk, P. J. M., & Giphart-Gassler, M. (2009) · Blood · doi:10.1182/blood-2009-03-211334 · Cited by 55
Self-citationTaslaman, L., & Nilsson, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046331 · Cited by 66
Klein, H., Ruckert, C., Kohlmann, A., Bullinger, L., Thiede, C., Haferlach, T., & Dugas, M. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-422 · Cited by 59
“As a result, biologically and clinically relevant subtypes of leukemia have been characterized based on their respective gene expression patterns [2-7].”
BackgroundInfluentialLin, S., Mulloy, J. C., & Goyama, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_11 · Cited by 60
Wagner, S., Vadakekolathu, J. N., Tasian, S. K., Altmann, H., Bornhäuser, M., Pockley, A. G., Ball, G., & Rutella, S. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018030726 · Cited by 55
Clinical Significance of the Most Common Chromosome Translocations in Adult Acute Myeloid Leukemia
Mrózek, K., & Bloomfield, C. D. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn003 · Cited by 64
Tobin, N. P., Foukakis, T., Petris, L. D., & Bergh, J. C. S. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12429 · Cited by 59
Schwind, S., Marcucci, G., Kohlschmidt, J., Radmacher, M. D., Mrózek, K., Maharry, K. S., Becker, H., Metzeler, K. H., Whitman, S. P., Wu, Y.-Z., et al. (2011) · Blood · doi:10.1182/blood-2011-06-357764 · Cited by 54
“Disease-free at 3 y, % (95% CI) 9 (2-21) 11 (2-28)”
InfluentialFLT3 inhibition as a targeted therapy for acute myeloid leukemia
Sanz, M. Á., Burnett, A. K., Lo‐Coco, F., & Löwenberg, B. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833118fd · Cited by 54
Self-citationPulikkan, J. A., Madera, D., Xue, L., Bradley, P. J., Landrette, S. F., Kuo, Y., Abbas, S., Zhu, L. J., Valk, P. J. M., & Castilla, L. H. (2012) · Blood · doi:10.1182/blood-2012-03-414649 · Cited by 61
Self-citationBrumatti, G., Salmanidis, M., Kok, C. H., Bilardi, R. A., Sandow, J. J., Silke, N., Mason, K. D., Visser, J. A. L., Jabbour, A. M., Glaser, S. P., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1306 · Cited by 59
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia
Marquis, M., Beaubois, C., Lavallée, V., Abrahamowicz, M., Danieli, C., Lemieux, S., Ahmad, I., Wei, A. H., Ting, S. B., Fleming, S. A., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0103-6 · Cited by 54
Yang, D., Li, Y., Xiao, H., Liu, Q., Zhang, M., Zhu, J., Ma, W., Yao, C., Wang, J., Wang, D., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm558 · Cited by 55
PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway
Zhou, J., Wu, J., Li, B., Liu, D., Yu, J., Yan, X., Zheng, S., Wang, J., Zhang, L., Zhang, L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.384 · Cited by 53
Self-citationYin, B., Delwel, R., Valk, P. J. M., Wallace, M. R., Loh, M. L., Shannon, K., & Largaespada, D. A. (2008) · Blood · doi:10.1182/blood-2008-03-144436 · Cited by 57
Self-citationRegulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation
Rishi, L., Hannon, M., Salomè, M., Hasemann, M. S., Frank, A.-K., Campos, J., Timoney, J., O’Connor, C., Cahill, M. R., Porse, B. T., et al. (2014) · Blood · doi:10.1182/blood-2013-07-511683 · Cited by 61
Hyde, R. K., Kamikubo, Y., Anderson, S. M., Kirby, M., Alemu, L., Zhao, L., & Liu, P. (2009) · Blood · doi:10.1182/blood-2009-06-227413 · Cited by 53
RPN1, a new reference gene for quantitative data normalization in lung and kidney cancer
Krasnov, G. S., Oparina, N. Y., Dmitriev, A. A., Kudryavtseva, A. V., Anedchenko, E. A., Кондратьева, Т. Т., Zabarovsky, E. R., & Senchenko, V. N. (2011) · Molecular Biology · doi:10.1134/s0026893311020129 · Cited by 53
“... of the data on several dozens cancer types of different locations represented in the Oncomine database [26, 27] showed that RPN1 mRNA levels dif� fered significantly between normal and tumor tissues only in bladder cancer (Sanchez�Carbayo Bladder 2, 157 specimens [36]), cervical and ovarian cancer (Welsh Ovarian,…”
BackgroundWang, W., Schwemmers, S., Hexner, E. O., & Pahl, H. L. (2010) · Blood · doi:10.1182/blood-2009-11-254664 · Cited by 63
SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness
Nguyen, C. H., Glüxam, T., Schlerka, A., Bauer, K., Grandits, A. M., Hackl, H., Dovey, O. M., Zöchbauer‐Müller, S., Cooper, J. L., Vassiliou, G. S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45579-0 · Cited by 58
Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology
Lindberg, J., af Klint, E., Ulfgren, A., Stark, A., Andersson, T., Nilsson, P., Klareskog, L., & Lundeberg, J. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1903 · Cited by 55
“Microarray (MA) technology allows the expression of thousands of genes to be monitored simultaneously and can thus increase the understanding of the complicated molecular processes of joint inflammation in more detail than has been possible with immunohistochemistry and related techniques [9-14].”
BackgroundEcotropic viral integration site 1, stem cell self‐renewal and leukemogenesis
Kataoka, K., & Kurokawa, M. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02303.x · Cited by 53
Margalit, O., Somech, R., Amariglio, N., & Rechavi, G. (2004) · Blood Reviews · doi:10.1016/j.blre.2004.11.003 · Cited by 60
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells
Tam, W. F., Gu, T., Chen, J., Lee, B. H., Bullinger, L., Fröhling, S., Wang, A. Z., Monti, S., Golub, T. R., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2007-07-103010 · Cited by 58
Vázquez, I., Maicas, M., Cervera, J., Agirre, X., Marín-Béjar, O., Marcotegui, N., Vicente, C., Lahortiga, I., Gomez-Benito, M., Carranza, C., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.040535 · Cited by 52
Chou, F., Griesinger, A. M., Wunderlich, M., Lin, S., Link, K. A., Shrestha, M., Goyama, S., Mizukawa, B. E., Shen, S., Marcucci, G., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403212 · Cited by 57
Winter, S. S., Jiang, Z., Khawaja, H. M., Griffin, T. C., Devidas, M., Asselin, B. L., & Larson, R. A. (2007) · Blood · doi:10.1182/blood-2006-12-059790 · Cited by 52
Heesch, S., Goekbuget, N., Stroux, A., Tanchez, J. O., Schlee, C., Burmeister, T., Schwartz, S., Blau, O., Keilholz, U., Busse, A., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016386 · Cited by 52
Mao, X., Cao, B., Wood, T. E., Hurren, R., Tong, J., Wang, X., Wang, W., Li, J., Jin, Y., Sun, W., et al. (2010) · Blood · doi:10.1182/blood-2010-05-284810 · Cited by 52
Biernacki, M. A., Marina, O., Zhang, W., Liu, F., Bruns, I., Cai, A., Neuberg, D. S., Canning, C. M., Alyea, E. P., Soiffer, R. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2303 · Cited by 52
“org Downloaded from normal epithelial cells (7); monocytes, neutrophils, and acute myelogenous leukemia (AML) cells (8); CD34 cells from normal donors (9–11); the K562 cell line(5); total PBMC (10); and total bone marrow (9, 12) from normal donors.”
BackgroundReporting bias when using real data sets to analyze classification performance
Yousefi, M. R., Hua, J., Sima, C., & Dougherty, E. R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp605 · Cited by 52
Transcription Factor Sp3 Knockout Mice Display Serious Cardiac Malformations
van Loo, P. F., Mahtab, E. A. F., Wisse, L. J., Hou, J., Grosveld, F. G., Suske, G., Philipsen, S., & Groot, A. C. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01350-07 · Cited by 58
“Data extraction and normalization were done as described previously ( 51 ) using Affymetrix Gene Chip Operating Software (GCOS) version 1.4.”
MethodInfluentialWu, Y. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh118 · Cited by 52
“We selected Affymetrix GeneChips for cross-platform comparison since they have been widely used for global gene expression profiling (6,7).”
BackgroundMethodMolecular signatures in acute myeloid leukemia
Mrózek, K., Radmacher, M. D., Bloomfield, C. D., & Marcucci, G. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257b42 · Cited by 51
Paz‐Priel, I., Cai, D. H., Wang, D., Kowalski, J., Blackford, A. L., Liu, H., Heckman, C. A., Gombart, A. F., Koeffler, H. P., Boxer, L. M., et al. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0111 · Cited by 55
Jelier, R., Jenster, G. W., Dorssers, L. C. J., Wouters, B. J., Hendriksen, P. J. M., Mons, B., Delwel, R., & Kors, J. A. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-14 · Cited by 54
“The first DNA microarray data set we analyzed, was the gene expression profile of the leukemic cells of a group of AML patients as identified in [23].”
BackgroundMethodInfluentialSelf-citationFull-intensity and reduced-intensity allogeneic stem cell transplantation in AML
Craddock, C. (2008) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705975 · Cited by 51
Arora, D., Köthe, S., van den Eijnden, M., van Huijsduijnen, R. H., Heidel, F. H., Fischer, T., Scholl, S., Tölle, B., Böhmer, S., Lennartsson, J., et al. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-19 · Cited by 51
“A published microarray dataset (GSE1159) was analyzed for PTP expression levels in FLT3 WT and FLT3 ITD samples [43].”
MethodAcute myeloid leukemia: A central role for the ETS factor ERG
Martens, J. H. A. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.05.014 · Cited by 57
Touw, I. P., & Erkeland, S. J. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300040 · Cited by 56
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.